420 related articles for article (PubMed ID: 17430686)
21. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Nishida T; Yoshidome K; Tori M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
23. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
Ahlman H; Nilsson O; Nilsson B
Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
[No Abstract] [Full Text] [Related]
24. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
25. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Raut CP; Posner M; Desai J; Morgan JA; George S; Zahrieh D; Fletcher CD; Demetri GD; Bertagnolli MM
J Clin Oncol; 2006 May; 24(15):2325-31. PubMed ID: 16710031
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis and management of gastrointestinal stromal tumors.
Bayraktar UD; Bayraktar S; Rocha-Lima CM
World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592
[TBL] [Abstract][Full Text] [Related]
27. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
28. [Focus on GIST management].
Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
[TBL] [Abstract][Full Text] [Related]
29. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
30. [Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].
Lu W; Lu WQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):309-12. PubMed ID: 22454182
[TBL] [Abstract][Full Text] [Related]
31. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G
J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855
[TBL] [Abstract][Full Text] [Related]
32. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
[TBL] [Abstract][Full Text] [Related]
33. Controversies in the surgical management of GIST in the era of imatinib.
Raut CP; Bertagnolli MM
Oncology (Williston Park); 2009 Jan; 23(1):69, 74-6. PubMed ID: 19283924
[TBL] [Abstract][Full Text] [Related]
34. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
[TBL] [Abstract][Full Text] [Related]
35. New therapeutic options in gastrointestinal stromal tumors.
Stein E; Aranha O; Agulnik M
Oncology (Williston Park); 2008 Feb; 22(2):206-11; discussion 215-6, 219. PubMed ID: 18409663
[TBL] [Abstract][Full Text] [Related]
36. Current management of GISTs.
Blanke C
Clin Adv Hematol Oncol; 2010 May; 8(5):334. PubMed ID: 20551892
[No Abstract] [Full Text] [Related]
37. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Caram MV; Schuetze SM
J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
[TBL] [Abstract][Full Text] [Related]
38. [A case of imatinib-resistant GIST treated by sunitinib].
Sakamoto Y; Akimoto H; Kojo M; Kawano H; Chinen Y; Morita K; Sugiyama M; Saeki H; Minami K; Soejima Y; Sakaguchi Y; Toh Y; Okamura T
Gan To Kagaku Ryoho; 2011 May; 38(5):827-30. PubMed ID: 21566447
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
[TBL] [Abstract][Full Text] [Related]
40. Perioperative treatment of gastrointestinal stromal tumors.
Fernandes Gdos S; Blanke CD; Freitas D; Guedes R; Hoff PM
Oncology (Williston Park); 2009 Jan; 23(1):54-61. PubMed ID: 19283922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
